|
1
|
Cree BA, Goodin DS and Hauser SL:
Neuromyelitis optica. Semin Neurol. 22:105–122. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Seze J, Lebrun C, Stojkovic T, Ferriby
D, Chatel M and Vermersch P: Is Devic's neuromyelitis optica a
separate disease? A comparative study with multiple sclerosis. Mult
Scler. 9:521–525. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hinson SR, Pittock SJ, Lucchinetti CF,
Roemer SF, Fryer JP, Kryzer TJ and Lennon VA: Pathogenic potential
of IgG binding to water channel extracellular domain in
neuromyelitis optica. Neurology. 69:2221–2231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marignier R, Nicolle A, Watrin C, Touret
M, Cavagna S, Varrin-Doyer M, Cavillon G, Rogemond V, Confavreux C,
Honnorat J and Giraudon P: Oligodendrocytes are damaged by
neuromyelitis optica immunoglobulin G via astrocyte injury. Brain.
133:2578–2591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parratt JD and Prineas JW: Neuromyelitis
optica: A demyelinating disease characterized by acute destruction
an regeneration of perivascular astrocytes. Mult Scler.
16:1156–1172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paul F, Jarius S, Aktas O, Bluthner M,
Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E,
Palace J, et al: Antibody to aquaporin 4 in the diagnosis of
neuromyelitis optica. PLoS Med. 4:e1332007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsuoka T, Matsushita T, Kawano Y,
Osoegawa M, Ochi H, Ishizu T, Minohara M, Kikuchi H, Mihara F,
Ohyagi Y and Kira J: Heterogeneity of aquaporin-4 autoimmunity and
spinal cord lesions in multiple sclerosis in Japanese. Brain.
130:1206–1223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nicchia GP, Mastrototaro M, Rossi A,
Pisani F, Tortorella C, Ruggieri M, Lia A, Trojano M, Frigeri A and
Svelto M: Aquaporin-4 orthogonal arrays of particles are the target
for neuromyelitis optica autoantibodies. Glia. 57:1363–1373. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trebst C, Berthele A, Jarius S, Trebst C,
Berthele A, Jarius S, Kümpfel T, Schippling S, Wildemann B and
Wilke C; Neuromyelitis optica Studiengruppe (NEMOS), : Diagnosis
and treatment of neuromyelitis optica. Consensus recommendations of
the neuromyelitis optica study group. Nervenarzt. 82:768–777.
2011.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wildemann B, Jarius S and Paul F:
Neuromyelitis optica. Nervenarzt. 84:436–441. 2013.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kimbrough DJ, Fujihara K, Jacob A,
Lana-Peixoto MA, Leite MI, Levy M, Marignier R, Nakashima I, Palace
J, de Seze J, et al: Treatment of neuromyelitis optica: Review and
recommendations. Mult Scler Relat Disord. 1:180–187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jarius S, Aboul-Enein F, Waters P, Kuenz
B, Hauser A, Berger T, Lang W, Reindl M, Vincent A and
Kristoferitsch W: Antibody to aquaporin-4 in the long-term course
of neuromyelitis optica. Brain. 131:3072–3080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bedi GS, Brown AD, Delgado SR, Usmani N,
Lam BL and Sheremata WA: Impact of rituximab on relapse rate and
disability in neuromyelitis optica. Mult Scler. 17:1225–1230. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim SH, Kim W, Li XF, Jung IJ and Kim HJ:
Repeated treatment with rituximab based on the assessment of
peripheral circulating memory B cells in patients with relapsing
neuromyelitis optica over 2 years. Arch Neurol. 68:1412–1420. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greenberg BM, Graves D, Remington G,
Hardeman P, Mann M, Karandikar N, Stuve O, Monson N and Frohman E:
Rituximab dosing and monitoring strategies in neuromyelitis optica
patients: Creating strategies for therapeutic success. Mult Scler.
18:1022–1026. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pellkofer H, Suessmair C, Schulze A,
Hohlfeld R and Kuempfel T: Course of neuromyelitis optica during
inadvertent pregnancy in a patient treated with rituximab. Mult
Scler. 15:1006–1008. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Costanzi C, Matiello M, Lucchinetti CF,
Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P and McKeon A:
Azathioprine: Tolerability, efficacy, and predictors of benefit in
neuromyelitis optica. Neurology. 77:659–666. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watanabe S, Misu T, Miyazawa I, Nakashima
I, Shiga Y, Fujihara K and Itoyama Y: Low-dose corticosteroids
reduce relapses in neuromyelitis optica: A retrospective analysis.
Mult Scler. 13:968–974. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bichuetti DB, Lobato de Oliveira EM,
Oliveira DM, Amorin de Souza N and Gabbai AA: Neuromyelitis optica
treatment: Analysis of 36 patients. Mult Scler. 67:1131–1136.
2010.
|
|
20
|
Mandler RN, Ahmed W and Dencoff JE:
Devic's neuromyelitis optica: A prospective study of seven patients
treated with prednisone and azathioprine. Neurology. 51:1219–1220.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jacob A, Matiello M, Weinshenker BG,
Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM,
Kantarci OH and Pittock SJ: Treatment of neuromyelitis optica with
mycophenolate mofetil: Retrospective analysis of 24 patients. Arch
Neurol. 66:1128–1133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kitley J, Elsone L, George J, Waters P,
Woodhall M, Vincent A, Jacob A, Leite MI and Palace J: Methotrexate
is an alternative to azathioprine in neuromyelitis optica spectrum
disorders with aquaporin-4 antibodies. J Neurol Neurosurg
Psychiatry. 84:918–921. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SH, Kim W, Park MS, Sohn EH, Li XF and
Kim HJ: Efficacy and safety of mitoxantrone in patients with highly
relapsing neuromyelitis optica. Arch Neurol. 68:473–479. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weinstock-Guttman B, Ramanathan M, Lincoff
N, Napoli SQ, Sharma J, Feichter J and Bakshi R: Study of
mitoxantrone for the treatment of recurrent neuromyelitis optica
(Devic disease). Arch Neurol. 63:957–963. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cabre P, Olindo S, Marignier R, Jeannin S,
Merle H and Smadja D; Aegis of French National Observatory of
Multiple Sclerosis, : Efficacy of mitoxantrone in neuromyelitis
optica spectrum: Clinical and neuroradiological study. J Neurol
Neurosurg Psychiatry. 84:511–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dörr J, Bitsch A, Schmailzl KJ, Chan A,
von Ahsen N, Hummel M, Varon R, Lill CM, Vogel HP, Zipp F and Paul
F: Severe cardiac failure in a patient with multiple sclerosis
following low-dose mitoxantrone treatment. Neurology. 73:991–993.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stroet A, Hemmelmann C, Starck M, Zettl U,
Dörr J, Friedemann P, Flachenecker P, Fleischer V, Zipp F, Nückel
H, et al: Incidence of therapy-related acute leukaemia in
mitoxantrone-treated multiple sclerosis patients in Germany. Ther
Adv Neurol Disord. 5:75–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stroet A, Gold R and Chan A: Acute myeloid
leukemia in Italian patients with multiple sclerosis treated with
mitoxantrone. Neurology. 78:933; author reply 933–934. 2012.
View Article : Google Scholar
|
|
29
|
Tradtrantip L, Zhang H, Saadoun S, Phuan
PW, Lam C, Papadopoulos MC, Bennett JL and Verkman AS: Anti-
aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis
optica. Ann Neurol. 71:314–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun M, Wang J, Zhou Y, Wang Z, Jiang Y and
Li M: Isotetrandrine reduces astrocyte cytotoxicity in
neuromyelitis optica by blocking the binding of NMO-IgG to
aquaporin 4. Neuroimmunomodulation. 23:98–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Solenov E, Watanabe H, Manley GT and
Verkman AS: Sevenfold-reduced osmotic water permeability in primary
astrocyte cultures from AQP-4-deficient mice, measured by a
fluorescence quenching method. Am J Physiol Cell Physiol.
286:C426–C432. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Su W, Wang J, Pisani F, Frigeri A
and Ma T: Detection of anti-aquaporin-4 autoantibodies in the sera
of Chinese neuromyelitis optica patients. Neural Regen Res.
8:708–713. 2013.PubMed/NCBI
|
|
33
|
Khan M, Yu B, Rasul A, Al Shawi A, Yi F,
Yang H and Ma T: Jaceosidin induces apoptosis in U87 glioblastoma
cells through G2/M phase arrest. Evid Based Complement Alternat
Med. 2012:7030342012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Swanson RA, Liu J, Miller JW, Rothstein
JD, Farrell K, Stein BA and Longuemare MC: Neuronal regulation of
glutamate transporter subtype expression in astrocytes. J Neurosci.
17:932–940. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lennon VA, Kryzer TJ, Pittock SJ, Verkman
AS and Hinson SR: IgG marker of optic-spinal multiple sclerosis
binds to the aquaporin-4 water channel. J Exp Med. 202:473–477.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lennon VA, Wingerchuk DM, Kryzer TJ,
Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I and Weinshenker
BG: A serum autoantibody marker of neuromyelitis optica:
Distinction from multiple sclerosis. Lancet. 364:2106–2112. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jarius S, Franciotta D, Bergamaschi R,
Wright H, Littleton E, Palace J, Hohlfeld R and Vincent A: NMO-IgG
in the diagnosis of neuromyelitis optica. Neurology. 68:1076–1077.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jarius S, Probst C, Borowski K, Franciotta
D, Wildemann B, Stoecker W and Wandinger KP: Standardized method
for the detection of antibodies to aquaporin-4 based on a highly
sensitive immunofluorescence assay employing recombinant target
antigen. J Neurol Sci. 291:52–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jarius S, Franciotta D, Paul F,
Bergamaschi R, Rommer PS, Ruprecht K, Ringelstein M, Aktas O,
Kristoferitsch W and Wildemann B: Testing for antibodies to human
aquaporin-4 by ELISA: Sensitivity, specificity, and direct
comparison with immunohistochemistry. J Neurol Sci. 320:32–37.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Waters P, Jarius S, Littleton E, Leite MI,
Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, et al:
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally
extensive transverse myelitis. Arch Neurol. 65:913–919. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Snoussi M, Dehmani A, Noumi E, Flamini G
and Papetti A: Chemical composition and antibiofilm activity of
Petroselinum crispum and Ocimum basilicum essential
oils against Vibrio spp. strains. Microb Pathog. 90:13–21. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chaudhary SK, Ceska O, Têtu C, Warrington
PJ, Ashwood- Smith MJ and Poulton GA: Oxypeucedanin, a major
furocoumarin in parsley, Petroselinum crispum. Planta Med.
52:462–464. 1986. View Article : Google Scholar
|
|
43
|
Mahmood S, Hussain S and Malik F: Critique
of medicinal conspicuousness of parsley (Petroselinum
crispum): A culinary herb of mediterranean region. Pak J Pharm
Sci. 27:193–202. 2014.PubMed/NCBI
|
|
44
|
Seelinger G, Merfort I and Schempp CM:
Anti-oxidant, anti-inflammatory and anti-allergic activities of
luteolin. Planta Med. 74:1667–1677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yuan CH, Filippova M, Tungteakkhun SS,
Duerksen-Hughes PJ and Krstenansky JL: Small molecule inhibitors of
the HPV16-E6 interaction with caspase 8. Bioorg Med Chem Lett.
22:2125–2129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jo JH, Jo JJ, Lee JM and Lee S:
Identification of absolute conversion to geraldol from fisetin and
pharmacokinetics in mouse. J Chromatogr B Analyt Technol Biomed
Life Sci. 1038:95–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
